CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Series A Preferred Stock [Member] Preferred Stock [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member] Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid in Capital Stock Options / Warrants [Member]	Additional Paid in Capital Preferred Stock [Member]	Retained Earnings [Member]	Total
Balance at Sep. 30, 2019	$ 50		$ 0	$ 33,369,424	$ 5,335,398	$ 3,811,700	$ (44,752,523)		$ (2,235,951)
Balance (in Shares) at Sep. 30, 2019	5,000		0	1,601,888
Net income (loss)							(63,121)		(63,121)
Balance at Mar. 31, 2020	$ 50		$ 0	$ 33,369,424	5,335,398	3,811,700	44,815,644		(2,299,072)
Balance (in Shares) at Mar. 31, 2020	5,000		0	1,601,888
Balance at Sep. 30, 2020	$ 0		$ 250	$ 33,369,424	11,710,398	4,210,960	(57,949,086)	$ 5,088,324	(3,569,730)
Balance (in Shares) at Sep. 30, 2020	0		25,000	1,603,492
Paid in Capital for StemVax Acquisition				$ 6,375,000	(6,375,000)
Common stock issued for StemVax Acquisition - from stock payable (in Shares)				7,500,000
Stock compensation cost				$ 936,000					936,000
Stock compensation cost (in Shares)				2,000,000
Common stock issued for Services		$ 50		$ 145,941					$ 145,941
Common stock issued for Services (in Shares)				311,945					311,945
Common Stock Issued - Subscriptions				$ 295,000					$ 295,000
Common Stock Issued - Subscriptions (in Shares)				1,440,905					1,440,905
Net income (loss)							(514,092)		$ (514,092)
Balance at Mar. 31, 2021			$ 250	$ 41,121,365	$ 5,335,398	$ 4,210,960	$ (58,463,178)	$ 5,088,324	$ (2,706,881)
Balance (in Shares) at Mar. 31, 2021			25,000	12,856,342